Austar Lifesciences Limited
AULSF
$0.07
$0.071,300.00%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 202.68M | 205.31M | 208.62M | 211.52M | 213.96M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 202.68M | 205.31M | 208.62M | 211.52M | 213.96M |
| Cost of Revenue | 161.78M | 163.99M | 166.74M | 170.14M | 173.17M |
| Gross Profit | 40.90M | 41.32M | 41.88M | 41.38M | 40.79M |
| SG&A Expenses | 32.84M | 32.97M | 33.21M | 35.20M | 37.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -3.34M | -3.47M | -3.61M | -2.90M | -2.17M |
| Total Operating Expenses | 197.75M | 200.43M | 203.79M | 209.73M | 215.23M |
| Operating Income | 4.93M | 4.87M | 4.83M | 1.78M | -1.27M |
| Income Before Tax | 5.85M | 4.39M | 2.94M | 171.10K | -2.60M |
| Income Tax Expenses | 1.29M | 1.17M | 1.06M | 766.80K | 477.30K |
| Earnings from Continuing Operations | 4.56 | 3.22 | 1.89 | -0.60 | -3.08 |
| Earnings from Discontinued Operations | -- | -- | -- | -3.34M | -6.68M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 305.10K | 325.90K | 348.30K | 376.40K | 404.00K |
| Net Income | 4.87M | 3.55M | 2.24M | -3.56M | -9.35M |
| EBIT | 4.93M | 4.87M | 4.83M | 1.78M | -1.27M |
| EBITDA | 9.23M | 9.12M | 9.04M | 5.81M | 2.57M |
| EPS Basic | 0.01 | 0.01 | 0.00 | -0.01 | -0.02 |
| Normalized Basic EPS | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.01 | 0.01 | 0.00 | -0.01 | -0.02 |
| Normalized Diluted EPS | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 2.05B | 2.05B | 2.05B | 2.05B | 2.05B |
| Average Diluted Shares Outstanding | 2.05B | 2.05B | 2.05B | 2.05B | 2.05B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |